Loading...
Loading...
Antares Pharma
ATRS today announced the issuance of U.S.
Patent 8,579,865. This new patent is related to a previously issued U.S.
patent 8,480,631, and includes additional claims that describe injection
devices for the subcutaneous delivery of methotrexate. The expiry date
for this patent is 2030. The issuance of this patent further protects
the OTREXUP™ injection system by describing the injector and
methods of use resulting in methotrexate blood levels bioequivalent to
needle and syringe injections. With the addition of this patent, there
are now 7 patents listed in the Orange Book related to OTREXUP™.
“We continue to make significant progress in our efforts to
patent-protect our first in-house proprietary product OTREXUP™,
as well
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in